{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:52:47Z","timestamp":1791201167403,"version":"4.2.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K10576"],"award-info":[{"award-number":["JP25K10576"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12185-026-04282-3","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:24:31Z","timestamp":1789838671000},"page":"456-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-0021","authenticated-orcid":false,"given":"Yuho","family":"Najima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"4282_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2003","unstructured":"McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts. Ann Intern Med. 2003;172:229\u201339.","journal-title":"Ann Intern Med"},{"key":"4282_CR2","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41409-020-01163-z","volume":"56","author":"M Yanada","year":"2021","unstructured":"Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 2021;56:1126\u201333.","journal-title":"Bone Marrow Transplant"},{"key":"4282_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329\u201336.","journal-title":"J Clin Oncol"},{"key":"4282_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383.","journal-title":"J Clin Oncol"},{"key":"4282_CR5","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","volume":"112","author":"HJ Kolb","year":"2008","unstructured":"Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371\u201383.","journal-title":"Blood"},{"key":"4282_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood.2021012412","volume":"141","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp Z, Chen YB. How I treat with maintenance therapy after allogeneic HCT. Blood. 2023;141:39\u201348.","journal-title":"Blood"},{"key":"4282_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12185-023-03596-w","volume":"118","author":"Y Najima","year":"2023","unstructured":"Najima Y. Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS. Int J Hematol. 2023;118:169\u201382.","journal-title":"Int J Hematol"},{"key":"4282_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12185-017-2364-4","volume":"107","author":"T Schroeder","year":"2018","unstructured":"Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107:138\u201350.","journal-title":"Int J Hematol"},{"key":"4282_CR9","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","volume":"119","author":"OC Goodyear","year":"2012","unstructured":"Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119:3361\u20139.","journal-title":"Blood"},{"key":"4282_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","volume":"22","author":"C Craddock","year":"2016","unstructured":"Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, et al. Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial. Biol Blood Marrow Transplant. 2016;22:385\u201390.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4282_CR11","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1002\/cncr.25500","volume":"116","author":"M de Lima","year":"2010","unstructured":"de Lima M, Giralt S, Thall PF, de Padua SL, Jones RB, Komanduri K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116:5420\u201331.","journal-title":"Cancer"},{"key":"4282_CR12","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","volume":"4","author":"B Oran","year":"2020","unstructured":"Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4:5580\u20138.","journal-title":"Blood Adv"},{"key":"4282_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","volume":"26","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26:381\u20139.","journal-title":"Leukemia"},{"key":"4282_CR14","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19:1668\u201379.","journal-title":"Lancet Oncol"},{"key":"4282_CR15","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s00277-022-04981-x","volume":"101","author":"Y Najima","year":"2022","unstructured":"Najima Y, Tachibana T, Takeda Y, Koda Y, Aoyama Y, Toya T, et al. Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study. Ann Hematol. 2022;101:2719\u201329.","journal-title":"Ann Hematol"},{"key":"4282_CR16","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","volume":"24","author":"M de Lima","year":"2018","unstructured":"de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transplant. 2018;24:2017\u201324.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4282_CR17","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383:2526\u201337.","journal-title":"N Engl J Med"},{"key":"4282_CR18","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","volume":"21","author":"I Pusic","year":"2015","unstructured":"Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2015;21:1761\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4282_CR19","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.19.03277","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020;38:4249\u201359.","journal-title":"J Clin Oncol"},{"key":"4282_CR20","doi-asserted-by":"publisher","first-page":"609.e1","DOI":"10.1016\/j.jtct.2025.12.951","volume":"32","author":"J Huang","year":"2026","unstructured":"Huang J, Xia Y, Xiang M, Zhang R, Yang Y, Chen H, et al. Acute myeloid leukemia patients with myelodysplasia-related gene mutations benefit from post-transplant hypomethylating agent maintenance. Transplant Cell Ther. 2026;32:609.e1-609.e12.","journal-title":"Transplant Cell Ther"},{"key":"4282_CR21","doi-asserted-by":"publisher","first-page":"997.e1","DOI":"10.1016\/j.jtct.2021.09.005","volume":"27","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, et al. Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation-a systematic review and meta-analysis. Transplant Cell Ther. 2021;27:997.e1-997.e11.","journal-title":"Transplant Cell Ther"},{"key":"4282_CR22","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/cas.15048","volume":"112","author":"Y Wei","year":"2021","unstructured":"Wei Y, Xiong X, Li X, Lu W, He X, Jin X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci. 2021;112:3636\u201344.","journal-title":"Cancer Sci"},{"key":"4282_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","volume":"58","author":"A Kent","year":"2023","unstructured":"Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023;58:849\u201354.","journal-title":"Bone Marrow Transplant"},{"key":"4282_CR24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","volume":"8","author":"JS Garcia","year":"2024","unstructured":"Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, et al. Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024;8:978\u201390.","journal-title":"Blood Adv"},{"key":"4282_CR25","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/bloodadvances.2025018631","volume":"10","author":"JS Garcia","year":"2026","unstructured":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, et al. Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML. Blood Adv. 2026;10:1548\u201358.","journal-title":"Blood Adv"},{"key":"4282_CR26","doi-asserted-by":"publisher","first-page":"e705","DOI":"10.1016\/S2352-3026(25)00172-3","volume":"12","author":"M Robin","year":"2025","unstructured":"Robin M, D\u2019Aveni M, Stamatoullas A, Raffoux E, Chevallier P, Garnier A, et al. Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025;12:e705\u201316.","journal-title":"Lancet Haematol"},{"key":"4282_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/bjh.13248","volume":"169","author":"G Oshikawa","year":"2015","unstructured":"Oshikawa G, Kakihana K, Saito M, Aoki J, Najima Y, Kobayashi T, et al. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2015;169:756\u20139.","journal-title":"Br J Haematol"},{"key":"4282_CR28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41409-024-02311-5","volume":"59","author":"S Kaito","year":"2024","unstructured":"Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, et al. Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies. Bone Marrow Transplant. 2024;59:1169\u201375.","journal-title":"Bone Marrow Transplant"},{"key":"4282_CR29","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/leu.2017.242","volume":"31","author":"G Bug","year":"2017","unstructured":"Bug G, Burchert A, Wagner EM, Kr\u00f6ger N, Berg T, G\u00fcller S, et al. Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Leukemia. 2017;31:2523\u20135.","journal-title":"Leukemia"},{"key":"4282_CR30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","volume":"30","author":"S Brunet","year":"2012","unstructured":"Brunet S, Labopin M, Esteve J, Cornelissen J, Soci\u00e9 G, Iori AP, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30:735\u201341.","journal-title":"J Clin Oncol"},{"key":"4282_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew NR, Baumgartner F, Braun L, O\u2019Sullivan D, Thomas S, Waterhouse M, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24:282\u201391.","journal-title":"Nat Med"},{"key":"4282_CR32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41409-022-01619-4","volume":"57","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Hasegawa Y, Hashimoto D, Senjo H, Kikuchi R, Chen X, et al. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2022;57:775\u201380.","journal-title":"Bone Marrow Transplant"},{"key":"4282_CR33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","volume":"133","author":"RF Schlenk","year":"2019","unstructured":"Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133:840\u201351.","journal-title":"Blood"},{"key":"4282_CR34","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","volume":"56","author":"RT Maziarz","year":"2021","unstructured":"Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56:1180\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"4282_CR35","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, R\u00f6llig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38:2993\u20133002.","journal-title":"J Clin Oncol"},{"key":"4282_CR36","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21:1201\u201312.","journal-title":"Lancet Oncol"},{"key":"4282_CR37","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10:e600\u201311.","journal-title":"Lancet Haematol"},{"key":"4282_CR38","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571\u201383.","journal-title":"Lancet"},{"key":"4282_CR39","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3324\/haematol.2024.286623","volume":"110","author":"RF Schlenk","year":"2025","unstructured":"Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, et al. Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial. Haematologica. 2025;110:2024\u201339.","journal-title":"Haematologica"},{"key":"4282_CR40","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1182\/bloodadvances.2025016444","volume":"10","author":"MJ Levis","year":"2026","unstructured":"Levis MJ, Erba HP, Montesinos P, Kim HJ, Vrhovac R, Patkowska E, et al. FLT3-ITD measurable residual disease from the QuANTUM-First trial. Blood Adv. 2026;10:917\u201328.","journal-title":"Blood Adv"},{"key":"4282_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ajh.24959","volume":"93","author":"BM Sandmaier","year":"2018","unstructured":"Sandmaier BM, Khaled S, Oran B, Gammon G, Trone D, Frankfurt O. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol. 2018;93:222\u201331.","journal-title":"Am J Hematol"},{"key":"4282_CR42","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766\u201375.","journal-title":"J Clin Oncol"},{"key":"4282_CR43","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood.2024025154","volume":"145","author":"MJ Levis","year":"2025","unstructured":"Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, et al. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood. 2025;145:2138\u201348.","journal-title":"Blood"},{"key":"4282_CR44","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1182\/bloodadvances.2025016306","volume":"9","author":"MJ Levis","year":"2025","unstructured":"Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, et al. Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia. Blood Adv. 2025;9:5123\u201333.","journal-title":"Blood Adv"},{"key":"4282_CR45","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/bloodadvances.2022008991","volume":"7","author":"T Terao","year":"2023","unstructured":"Terao T, Matsuoka KI, Ueda H, Matsumura A, Matsubara C, Kondo K, et al. Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R\/R FLT3mut AML. Blood Adv. 2023;7:681\u20136.","journal-title":"Blood Adv"},{"key":"4282_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100141","volume":"2","author":"T Terao","year":"2025","unstructured":"Terao T, Matsuoka KI, Kondo T, Maeda Y. Three-year follow-up of low-dose, early-start gilteritinib maintenance in posttransplant patients with R\/R FLT3 mut AML. Blood Neoplasia. 2025;2:100141.","journal-title":"Blood Neoplasia"},{"key":"4282_CR47","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1016\/j.clml.2026.03.007","volume":"26","author":"A Jinguji","year":"2026","unstructured":"Jinguji A, Kurosawa S, Toya T, Kato K, Sadaga Y, Kondo K, et al. Changes in outcomes of allogeneic hematopoietic stem cell transplantation for FLT3-ITD-mutated acute myeloid leukemia in the FLT3 inhibitor era. Clin Lymphoma Myeloma Leuk. 2026;26:e740-e751.e6.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4282_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.03.042","author":"Y Arai","year":"2026","unstructured":"Arai Y, Ohbiki M, Kurata M, Ota S, Tanaka M, Imada K, et al. Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapse\/refractory FLT3-mutated acute myeloid leukemia. Transplant Cell Ther. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.03.042.","journal-title":"Transplant Cell Ther"},{"key":"4282_CR49","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","volume":"29","author":"AT Fathi","year":"2023","unstructured":"Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, et al. Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia. Clin Cancer Res. 2023;29:2034\u201342.","journal-title":"Clin Cancer Res"},{"key":"4282_CR50","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","volume":"6","author":"AT Fathi","year":"2022","unstructured":"Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, et al. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022;6:5857\u201365.","journal-title":"Blood Adv"},{"key":"4282_CR51","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1200\/JCO.22.00181","volume":"40","author":"A Mishra","year":"2022","unstructured":"Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022;40:3985\u201393.","journal-title":"J Clin Oncol"},{"key":"4282_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43:75\u201384.","journal-title":"J Clin Oncol"},{"key":"4282_CR53","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.2025029712","volume":"147","author":"V Fetsch","year":"2026","unstructured":"Fetsch V, Schw\u00f6bel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, et al. Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. Blood. 2026;147:584\u2013601.","journal-title":"Blood"},{"key":"4282_CR54","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"MH Gilleece","year":"2018","unstructured":"Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Soci\u00e9 G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93:1142\u201352.","journal-title":"Am J Hematol"},{"key":"4282_CR55","doi-asserted-by":"publisher","first-page":"839.e1","DOI":"10.1016\/j.jtct.2021.06.029","volume":"27","author":"T Guillaume","year":"2021","unstructured":"Guillaume T, Th\u00e9pot S, Peterlin P, Ceballos P, Bourgeois AL, Garnier A, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome. Transplant Cell Ther. 2021;27:839.e1-839.e6.","journal-title":"Transplant Cell Ther"},{"key":"4282_CR56","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","volume":"21","author":"T Schroeder","year":"2015","unstructured":"Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2014a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant. 2015;21:653\u201360.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4282_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1521895","volume":"16","author":"Y Uchibori","year":"2025","unstructured":"Uchibori Y, Kurosawa S, Najima Y, Haraguchi K, Sadato D, Hirama C, et al. Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience. Front Immunol. 2025;16:1521895.","journal-title":"Front Immunol"},{"key":"4282_CR58","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMoa0811036","volume":"361","author":"L Vago","year":"2009","unstructured":"Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478\u201388.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04282-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04282-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04282-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:02:50Z","timestamp":1791198170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04282-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4282"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04282-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"29 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has received consulting fees from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and AbbVie GK; and payment or honoraria for lectures, presentations, or educational events from AbbVie GK, Amgen Inc., Astellas Pharma Inc., Asahi Kasei Therapeutics Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., JCR Pharma Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Sumitomo Pharma Co., Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}